Inhalation Sciences AB (ISAB) received its first order for a preclinical dissolution study using its high-precision DissolvIt technology from a returning customer who is one of the world's top 10 big pharma companies developing inhaled pharmaceuticals. The order is worth EUR 57,000 - over SEK 600,000. This is the first time the long-term client has requested a preclinical dissolution study from ISAB, having previously carried out such studies using in-house technology.

The new study will use DissolvIt - ISAB's unique, highly sensitive dissolution testing technology that generates high-precision data in the preclinical phase that can accurately predict how inhaled substances will perform in the clinical phase, reducing attrition, risk and costs. DissolvIt is being evaluated in an FDA BAA (Broad Agency Announcement) contract research project and it was also presented by ISAB CSO Per Gerde at an FDA GDUFA (Generic Drug User Fee Amendments) webinar on May 20th 2024 to a large audience of specialist industry professionals.